While the number of clinical trials in this area has increased in recent years, there remains an urgent and unmet need for new therapies. This article aims to identify key methodological, practical, and ethical issues involved in IPF clinical trials, focusing on country and site identification, feasibility, and study design. Approaches for mitigating these challenges will also be described.

Authors:

Vikki Brandi, PA, DHSc,
Therapeutic Strategy Lead,
Allergy & Respiratory Center
of Excellence

Juan Gispert, MD, Senior
Medical Director and Chair,
Allergy & Respiratory Center
of Excellence, Quintiles